Cooper Companies (COO) Sets New 1-Year High at $281.75

Cooper Companies Inc (NYSE:COO)’s share price reached a new 52-week high on Friday . The stock traded as high as $281.75 and last traded at $279.31, with a volume of 9959 shares trading hands. The stock had previously closed at $277.42.

COO has been the topic of several recent analyst reports. Wells Fargo & Co lifted their price objective on Cooper Companies from $290.00 to $295.00 and gave the company an “outperform” rating in a report on Monday, November 12th. Zacks Investment Research cut Cooper Companies from a “hold” rating to a “sell” rating in a report on Monday, September 3rd. BMO Capital Markets lifted their price objective on Cooper Companies from $280.00 to $285.00 and gave the company an “outperform” rating in a report on Friday, August 31st. Raymond James lifted their price objective on Cooper Companies from $270.00 to $300.00 and gave the company an “outperform” rating in a report on Friday, September 21st. Finally, Oppenheimer set a $270.00 price objective on Cooper Companies and gave the company a “hold” rating in a report on Friday, August 31st. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Cooper Companies presently has a consensus rating of “Buy” and an average target price of $276.22.

The company has a market cap of $13.63 billion, a P/E ratio of 28.75, a P/E/G ratio of 2.12 and a beta of 0.75. The company has a quick ratio of 1.54, a current ratio of 2.58 and a debt-to-equity ratio of 0.70.

Cooper Companies (NYSE:COO) last released its earnings results on Thursday, August 30th. The medical device company reported $3.00 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.07 by ($0.07). The firm had revenue of $660.00 million during the quarter, compared to the consensus estimate of $653.44 million. Cooper Companies had a net margin of 5.23% and a return on equity of 17.53%. As a group, equities analysts forecast that Cooper Companies Inc will post 11.61 earnings per share for the current year.

In other Cooper Companies news, Director Robert S. Weiss sold 58,543 shares of the business’s stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $252.82, for a total value of $14,800,841.26. Following the sale, the director now owns 157,710 shares in the company, valued at approximately $39,872,242.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Randal Golden sold 1,731 shares of the company’s stock in a transaction that occurred on Thursday, September 27th. The stock was sold at an average price of $275.86, for a total value of $477,513.66. Following the sale, the vice president now owns 1,154 shares in the company, valued at approximately $318,342.44. The disclosure for this sale can be found here. Insiders sold a total of 80,809 shares of company stock worth $20,740,667 in the last 90 days. Company insiders own 1.60% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Bradley Foster & Sargent Inc. CT raised its stake in shares of Cooper Companies by 10.1% during the 3rd quarter. Bradley Foster & Sargent Inc. CT now owns 2,184 shares of the medical device company’s stock worth $605,000 after purchasing an additional 200 shares in the last quarter. Penserra Capital Management LLC raised its stake in shares of Cooper Companies by 16.5% during the 3rd quarter. Penserra Capital Management LLC now owns 1,564 shares of the medical device company’s stock worth $433,000 after purchasing an additional 221 shares in the last quarter. Mackenzie Financial Corp raised its stake in shares of Cooper Companies by 21.9% during the 3rd quarter. Mackenzie Financial Corp now owns 1,237 shares of the medical device company’s stock worth $343,000 after purchasing an additional 222 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its stake in shares of Cooper Companies by 6.8% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,622 shares of the medical device company’s stock worth $853,000 after purchasing an additional 232 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. raised its stake in shares of Cooper Companies by 1.3% during the 2nd quarter. Nomura Asset Management Co. Ltd. now owns 19,770 shares of the medical device company’s stock worth $4,655,000 after purchasing an additional 262 shares in the last quarter. Institutional investors own 99.84% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2018/12/02/cooper-companies-coo-sets-new-1-year-high-at-281-75.html.

Cooper Companies Company Profile (NYSE:COO)

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Further Reading: What is the S&P 500 Index?

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit